The estimated Net Worth of Milton J Wallace is at least $10.5 Milhão dollars as of 29 May 2012. Milton Wallace owns over 11,100 units of Catalyst Pharmaceuticals Inc stock worth over $10,492,521 and over the last 18 years Milton sold CPRX stock worth over $0.
Milton has made over 9 trades of the Catalyst Pharmaceuticals Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently Milton bought 11,100 units of CPRX stock worth $6,327 on 29 May 2012.
The largest trade Milton's ever made was buying 125,000 units of Catalyst Pharmaceuticals Inc stock on 24 May 2012 worth over $100,000. On average, Milton trades about 14,091 units every 119 days since 2007. As of 29 May 2012 Milton still owns at least 539,184 units of Catalyst Pharmaceuticals Inc stock.
You can see the complete history of Milton Wallace stock trades at the bottom of the page.
Milton's mailing address filed with the SEC is 220 MIRACLE MILE, SUITE 234, , CORAL GABLES, FL, 33134.
Over the last 18 years, insiders at Catalyst Pharmaceuticals Inc have traded over $35,595,986 worth of Catalyst Pharmaceuticals Inc stock and bought 7,401,098 units worth $7,307,159 . The most active insiders traders include Pharmaceutical Inc Biomarin, Patrick J Mcenany, eSteve Miller. On average, Catalyst Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $1,097,019. The most recent stock trade was executed by David S Tierney on 21 August 2024, trading 15,000 units of CPRX stock currently worth $60,150.
catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso
Catalyst Pharmaceuticals Inc executives and other stock owners filed with the SEC include: